DGAP-Adhoc: SYGNIS AG successfully completes Rights

SYGNIS AG / Key word(s): Capital Increase 10.12.2015 19:30 Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Ad hoc announcement according to § 15 WpHG --------------------------------------------------------------------------- NOT FOR DISTRIBUTION, PUBLICATION, OR TRANSMISSION IN USA, CANADA, JAPAN AND AUSTRALIA SYGNIS AG successfully completes Rights Offering and Private Placement - Rights offering and private placement raise EUR 5.6 million - Gross proceeds secure funds for working capital needs - Major shareholder Genetrix S.L., Spain, contributes EUR 0.6 million in kind by swapping its shareholder loan into equity Madrid, Spain and Heidelberg, Germany, December 10, 2015 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that the Company has successfully completed its rights offering and the subsequent private placement. A total number of 2,962,552 shares were placed at a subscription price of EUR 1.90 per share. In a cash capital increase 2,962,552 offered shares were placed with existing shareholders in a rights issue and with selected new institutional investors in a subsequent rump placement, which resulted in gross proceeds of more than EUR 5.6 million. Furthermore, a total of 315,789 consideration shares will be issued at the same issue price of EUR 1.90 by way of a capital increase against contributions in kind in order to swap the shareholder loan from the main shareholder Genetrix S.L., Spain, of approximately EUR 0.6 million into equity. Thus, the capital increase amounted to EUR 6.2 Mio. in total. By completion of this transaction, including the contribution in kind, the Company's share capital will increase from EUR 13,494,934.00 composed of 13,494,934 no-par value bearer shares, to EUR 16,773,275.00 composed of 16,773,275 shares, by issuing 3,278,341 new shares while partially utilising authorized capital. The new shares carry full dividend rights as of January 1, 2015. SYGNIS plans to use the gross proceeds of EUR 5.6 million to finance the expansion of its commercialization activities and customer base worldwide, especially to the US, to further progress its product portfolio and also includes the repayment of soft loans. **** End of ad hoc announcement **** For further information please contact: SYGNIS AG MC Services AG Pilar de la Huerta Raimund Gabriel CEO/CFO Managing Partner Phone: +34 91 192 36 50 Phone: +49 89 210228 30 Email: pdelahuerta@sygnis.com Email: raimund.gabriel@mc-services.eu About SYGNIS AG: www.sygnis.com SYGNIS, headquartered in Germany and Spain, specializes on the development and commercialization of innovative products for DNA amplification and sequencing. Based on its proprietary technologies, SYGNIS has developed a commercial product portfolio addressing key challenges in the fast growing fields of molecular biology and next generation sequencing applications. Key products include the TruePrime(TM) product line and SensiPhi(R), licensed to an industry leading partner, for whole genome DNA amplification and sequencing as well as the SunScript(TM) Reverse Transcriptase product family to convert genetic information from RNA molecules back to DNA. SYGNIS AG is listed at the German Stock Exchange in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03). ### This document is not a securities prospectus and the information contained therein does not constitute an offer to sell or a solicitation of an offer to purchase any securities of SYGNIS AG in Federal Republic of Germany nor under any other jurisdiction, in particular not where such kind of offer or solicitation is prohibited or lacks the required permission. Potential investors in securities of SYGNIS AG are asked to familiarize themselves with and to observe the respective restrictions. A decision to invest in the securities of SYGNIS AG should only be made on the basis of the securities prospectus detailing the public offering of securities of SYGNIS AG in the Federal Republic of Germany, which is published on www.sygnis.com in the section "investors". The information in this document may not be disseminated outside the Federal Republic of Germany in particular not in the United States, to US Persons (as defined in regulation S of the US Securities Act of 1933) or to publications with a general circulation in the United States with the exception of a such disclosures or announcements outside the Federal Republic of Germany which have to be made under the respective mandatory law. Any person who fails to comply with these restrictions may violate the security laws of certain jurisdictions, in particular of the United States. Securities in SYGNIS AG are not publicly offered outside the Federal Republic of Germany. ### 10.12.2015 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- Language: English Company: SYGNIS AG Waldhofer Str. 104 69123 Heidelberg Germany Phone: +49 (0) 6221 3540 125 Fax: +49 (0) 6221 3540 127 E-mail: investors@sygnis.com Internet: www.sygnis.com ISIN: DE000A1RFM03 WKN: A1RFM0 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------